154 related articles for article (PubMed ID: 22404545)
1. Infliximab for the treatment of psoriasis in the U.K.: 9 years' experience of infusion reactions at a single centre.
Wee JS; Petrof G; Jackson K; Barker JN; Smith CH
Br J Dermatol; 2012 Aug; 167(2):411-6. PubMed ID: 22404545
[TBL] [Abstract][Full Text] [Related]
2. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
4. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo.
Kalb RE; Gurske J
J Am Acad Dermatol; 2005 Oct; 53(4):616-22. PubMed ID: 16198781
[TBL] [Abstract][Full Text] [Related]
5. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
Dalaker M; Bonesrønning JH
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
[TBL] [Abstract][Full Text] [Related]
6. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
7. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions.
Lecluse LL; Piskin G; Mekkes JR; Bos JD; de Rie MA
Br J Dermatol; 2008 Sep; 159(3):527-36. PubMed ID: 18627374
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
DE Oliveira JP; Levy A; Morel P; Guibal F
J Dermatol; 2008 Sep; 35(9):575-80. PubMed ID: 18837702
[TBL] [Abstract][Full Text] [Related]
9. Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study.
Smith CH; Jackson K; Bashir SJ; Perez A; Chew AL; Powell AM; Wain M; Barker JN
Br J Dermatol; 2006 Jul; 155(1):160-9. PubMed ID: 16792769
[TBL] [Abstract][Full Text] [Related]
10. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
11. Long-term management of generalized pustular psoriasis with infliximab: case series.
Routhouska SB; Sheth PB; Korman NJ
J Cutan Med Surg; 2008; 12(4):184-8. PubMed ID: 18627699
[TBL] [Abstract][Full Text] [Related]
12. Use of infliximab in the treatment of psoriasis.
Lee MR; Cooper AJ
Australas J Dermatol; 2004 Aug; 45(3):193-5. PubMed ID: 15250904
[No Abstract] [Full Text] [Related]
13. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
14. Infliximab in the treatment of psoriasis in patients previously treated with etanercept.
Haitz KA; Kalb RE
J Am Acad Dermatol; 2007 Jul; 57(1):120-5. PubMed ID: 17482715
[TBL] [Abstract][Full Text] [Related]
15. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.
Duburque C; Lelong J; Iacob R; Seddik M; Desreumaux P; Fournier C; Wallaert B; Cortot A; Colombel JF
Aliment Pharmacol Ther; 2006 Sep; 24(5):851-8. PubMed ID: 16918890
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab].
Bermejo F; López San Román A; Algaba A; van Domselaar M; Carneros JA; Rivero M; Piqueras B; Valer MP
Gastroenterol Hepatol; 2008 Dec; 31(10):629-32. PubMed ID: 19174078
[TBL] [Abstract][Full Text] [Related]
17. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
[TBL] [Abstract][Full Text] [Related]
18. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
[TBL] [Abstract][Full Text] [Related]
19. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients.
Krathen RA; Berthelot CN; Hsu S
J Drugs Dermatol; 2006 Mar; 5(3):251-4. PubMed ID: 16573258
[TBL] [Abstract][Full Text] [Related]
20. Predictors of infusion reactions during infliximab treatment in patients with arthritis.
Kapetanovic MC; Larsson L; Truedsson L; Sturfelt G; Saxne T; Geborek P
Arthritis Res Ther; 2006; 8(4):R131. PubMed ID: 16869978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
